| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NR1D2 |
| Uniprot No | Q14995 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-579aa |
| 氨基酸序列 | MEVNAGGVIA YISSSSSASS PASCHSEGSE NSFQSSSSSV PSSPNSSNSD TNGNPKNGDL ANIEGILKND RIDCSMKTSK SSAPGMTKSH SGVTKFSGMV LLCKVCGDVA SGFHYGVHAC EGCKGFFRRS IQQNIQYKKC LKNENCSIMR MNRNRCQQCR FKKCLSVGMS RDAVRFGRIP KREKQRMLIE MQSAMKTMMN SQFSGHLQND TLVEHHEQTA LPAQEQLRPK PQLEQENIKS SSPPSSDFAK EEVIGMVTRA HKDTFMYNQE QQENSAESMQ PQRGERIPKN MEQYNLNHDH CGNGLSSHFP CSESQQHLNG QFKGRNIMHY PNGHAICIAN GHCMNFSNAY TQRVCDRVPI DGFSQNENKN SYLCNTGGRM HLVCPLSKSP YVDPHKSGHE IWEEFSMSFT PAVKEVVEFA KRIPGFRDLS QHDQVNLLKA GTFEVLMVRF ASLFDAKERT VTFLSGKKYS VDDLHSMGAG DLLNSMFEFS EKLNALQLSD EEMSLFTAVV LVSADRSGIE NVNSVEALQE TLIRALRTLI MKNHPNEASI FTKLLLKLPD LRSLNNMHSE ELLAFKVHP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NR1D2(Rev-Erbβ)重组蛋白的3篇代表性文献，涵盖其功能、结构及应用研究：
---
1. **文献名称**：*Structural characterization of the human nuclear receptor NR1D2 (Rev-Erbβ) ligand-binding domain*
**作者**：Zhu J, et al.
**摘要**：本研究通过重组表达并纯化人源NR1D2的配体结合域(LBD)，利用X射线晶体学解析其三维结构，揭示了其与内源性配体血红素结合的分子机制，为靶向NR1D2的药物设计提供了结构基础。
2. **文献名称**：*Recombinant NR1D2 protein modulates circadian gene expression in vitro*
**作者**：Kojetin DJ, et al.
**摘要**：通过在大肠杆菌中重组表达NR1D2蛋白，研究者证实其在体外可通过结合特定DNA序列(RORE元件)抑制生物钟相关基因(如Bmal1)的转录活性，揭示了NR1D2在昼夜节律调控中的直接作用。
3. **文献名称**：*Development of a mammalian cell-based system for high-yield production of functional Rev-Erbβ recombinant protein*
**作者**：Zhang Y, et al.
**摘要**：该研究优化了NR1D2在哺乳动物细胞中的重组表达系统，成功获得高纯度、具有配体结合活性的蛋白，并用于筛选小分子调控剂，为代谢性疾病治疗提供工具蛋白。
---
**注**：以上文献为示例，实际引用需根据具体研究内容检索PubMed或Web of Science获取最新论文。若需进一步协助文献检索，可提供更详细的研究方向。
**Background of NR1D2 Recombinant Protein**
NR1D2 (Nuclear Receptor Subfamily 1 Group D Member 2), also known as Rev-Erbβ, is a member of the nuclear receptor superfamily and functions as a transcriptional repressor. It plays a critical role in regulating circadian rhythms, metabolism, and inflammatory responses. Structurally, NR1D2 contains a DNA-binding domain (DBD) and a ligand-binding domain (LBD), enabling it to bind specific DNA response elements (RevRE/RORE) and recruit corepressors to suppress target gene expression. Unlike many nuclear receptors, NR1D2 lacks a classical activation domain and primarily operates as a constitutive repressor.
Recombinant NR1D2 protein is engineered for in vitro studies to dissect its molecular interactions, structural dynamics, and regulatory mechanisms. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), the recombinant protein retains functional domains required for DNA binding, ligand interaction (e.g., heme or synthetic agonists), and coregulator recruitment. Its applications include investigating circadian clock circuitry, metabolic pathways (e.g., lipid/glucose homeostasis), and immune modulation.
Research highlights NR1D2's involvement in diseases such as metabolic syndrome, cancer, and neurological disorders, making it a therapeutic target. Studies using recombinant NR1D2 have elucidated its role in repressing genes like *BMAL1* and *CCND1*, linking it to circadian disruption and cell cycle dysregulation. Challenges in working with NR1D2 include its instability in solution and dependence on post-translational modifications (e.g., phosphorylation) for activity. Recent advances in structural biology, leveraging recombinant protein, have aided in designing synthetic ligands to modulate its function, offering potential for chronotherapy and metabolic disease treatment.
×
